Prokidney announces strategic updates to its phase 3 program to accelerate rilparencel's registrational path to potential approval in the u.s.

Winston-salem, n.c., sept. 03, 2024 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (ckd), today announced strategic updates to its phase 3 program for rilparencel, an investigational treatment to potentially preserve kidney function in patients with type 2 diabetes and advanced ckd.
PROK Ratings Summary
PROK Quant Ranking